{"id":5372,"date":"2025-06-24T15:24:44","date_gmt":"2025-06-24T13:24:44","guid":{"rendered":"https:\/\/regen.mediartia.com\/research-development-7\/"},"modified":"2025-11-24T13:56:55","modified_gmt":"2025-11-24T12:56:55","slug":"alzheimer-pathophysiology","status":"publish","type":"page","link":"https:\/\/regen.mediartia.com\/en\/alzheimer-pathophysiology\/","title":{"rendered":"RESEARCH &amp; DEVELOPMENT"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row equal_height=&#8221;yes&#8221; content_placement=&#8221;top&#8221; custom_css_code=&#8221;LmdlbS1pbWFnZS1jZW50ZXJlZC1ib3glMjAlN0IlMEElMjAlMjAlMjAlMjBtYXJnaW4tYm90dG9tJTNBJTIwMCUzQiUwQSU3RCUwQS5pbWctYm9yZGVyLXJhZGl1cyUyMGltZyU3QiUwQSUyMCUyMCUyMCUyMGJvcmRlci1yYWRpdXMlM0ElMjAzM3B4JTNCJTBBJTdEJTBBLmN1c3RvbS1pbmZvdGV4dCUyMCU3QiUwQSUyMCUyMCUyMCUyMHdpZHRoJTNBJTIwMjIwcHglM0IlMEElN0QlMEElNDBtZWRpYSUyOG1heC13aWR0aCUzQSUyMDk5MXB4JTI5JTdCJTBBJTIwJTIwJTIwJTIwLmN1c3RvbS1pbmZvdGV4dCUyMCU3QiUwQSUyMCUyMCUyMCUyMCUyMCUyMCUyMCUyMHdpZHRoJTNBJTIwMjAwcHglM0IlMEElMjAlMjAlMjAlMjAlN0QlMEElN0Q=&#8221; thegem_revesrse_columns_mobile=&#8221;true&#8221; css=&#8221;.vc_custom_1751013794817{margin-bottom: 0px !important;padding-top: 85px !important;padding-bottom: 85px !important;}&#8221; tablet_padding_top=&#8221;160&#8243; el_class=&#8221;CONTENEDORPIRATA&#8221; mobile_padding_top=&#8221;45&#8243;][vc_column width=&#8221;1\/2&#8243; css=&#8221;.vc_custom_1750698481768{padding-top: 0px !important;padding-right: 75px !important;}&#8221; tablet_padding_right=&#8221;42&#8243; mobile_padding_bottom=&#8221;60&#8243; mobile_padding_right=&#8221;21&#8243; el_class=&#8221;INTROPIRATA&#8221;]<div class=\"thegem-te-heading thegem-custom-6a210883a13331121\" ><div id=\"thegem-heading-6a210883a12fd\" class=\"thegem-heading title-h2 vc_custom_1750754812154\" style=\"text-align: left;\" ><span>THERAPEUTIC DEVELOPMENT<\/span><\/div><style type=\"text\/css\">#thegem-heading-6a210883a12fd {margin: 0;}#thegem-heading-6a210883a12fd a:hover, #thegem-heading-6a210883a12fd a:hover span.colored {color: var(--thegem-to-menu-level1-color-hover, #00BCD4) !important;}<\/style><\/div><style>@media screen and (max-width: 1023px) {.thegem-te-heading.thegem-custom-6a210883a13331121{display: block!important;}}@media screen and (max-width: 767px) {.thegem-te-heading.thegem-custom-6a210883a13331121{display: block!important;}}@media screen and (max-width: 1023px) {.thegem-te-heading.thegem-custom-6a210883a13331121{position: relative !important;}}@media screen and (max-width: 767px) {.thegem-te-heading.thegem-custom-6a210883a13331121{position: relative !important;}}<\/style>[vc_column_text css=&#8221;&#8221;]<\/p>\n<h4 style=\"text-align: left;\"><span style=\"color: #69abb4;\"><strong><span style=\"color: #aa689e;\">ALZHEIMER&#8217;S DISEASE<\/span> <\/strong><\/span><\/h4>\n<p>[\/vc_column_text]<div class=\"thegem-te-heading thegem-custom-6a210883a14525428\" ><div id=\"thegem-heading-6a210883a1419\" class=\"thegem-heading text-body\" style=\"text-align: left;\" ><span>Dementia of the Alzheimer&#039;s type and related syndromes represent a major public health issue, with 57 million cases worldwide, including 1.2 million in France. These figures are set to triple by 2050 as the population ages. <br \/>\nA progressive neurodegenerative pathology affecting the brain, Alzheimer&#039;s disease mainly manifests itself through memory impairment, but also impacts language, reasoning, behavior and autonomy. A source of morbidity, disability and mortality, it has major social and economic consequences, with an estimated annual global cost of $1,300 billion. <\/span><\/div><style type=\"text\/css\">#thegem-heading-6a210883a1419 {margin: 0;}#thegem-heading-6a210883a1419 a:hover, #thegem-heading-6a210883a1419 a:hover span.colored {color: var(--thegem-to-menu-level1-color-hover, #00BCD4) !important;}<\/style><\/div><style>@media screen and (max-width: 1023px) {.thegem-te-heading.thegem-custom-6a210883a14525428{display: block!important;}}@media screen and (max-width: 767px) {.thegem-te-heading.thegem-custom-6a210883a14525428{display: block!important;}}@media screen and (max-width: 1023px) {.thegem-te-heading.thegem-custom-6a210883a14525428{position: relative !important;}}@media screen and (max-width: 767px) {.thegem-te-heading.thegem-custom-6a210883a14525428{position: relative !important;}}<\/style>[\/vc_column][vc_column width=&#8221;1\/2&#8243; css=&#8221;.vc_custom_1750698153438{padding-top: 90px !important;}&#8221; mobile_padding_top=&#8221;175&#8243; el_class=&#8221;IMAGENPIRATA&#8221;]<div class=\"centered-box gem-image-centered-box\" ><div class=\"gem-image gem-wrapbox gem-wrapbox-style-default gem-wrapbox-position-centered img-border-radius thegem-custom-6a210883a14ad8088\"  style=\"\" ><div class=\"gem-wrapbox-inner \" ><img class=\"gem-wrapbox-element img-responsive\" src=\"https:\/\/regen.mediartia.com\/wp-content\/uploads\/2025\/11\/Woman-8-buste-et-ventre.jpg\" alt=\"\"\/><\/div><\/div><\/div>[\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; custom_css_code=&#8221;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&#8221; css=&#8221;.vc_custom_1750698736234{margin-bottom: 0px !important;padding-top: 85px !important;padding-bottom: 85px !important;background-color: #FFFFFF !important;}&#8221;][vc_column css=&#8221;.vc_custom_1726578677849{padding-top: 0px !important;}&#8221;][vc_row_inner content_placement=&#8221;bottom&#8221;][vc_column_inner]<style type=\"text\/css\">.thegem-button-6a210883a16f01687 .gem-button svg {fill: #000000;}<\/style><div class=\"gem-button-container gem-button-position-left thegem-button-6a210883a16f01687 QUITARLINK   \"  ><a class=\"gem-button gem-button-size-small gem-button-style-flat gem-button-text-weight-normal\" data-ll-effect=\"drop-right-without-wrap\" style=\"border-radius: 0px;background-color: #DDC3D8;color: #000000;\" onmouseleave=\"this.style.backgroundColor='#DDC3D8';this.style.color='#000000';\" onmouseenter=\"\" href=\"\" target=\"_self\" role=\"button\">Pathophysiology<\/a><\/div> [\/vc_column_inner][\/vc_row_inner][vc_row_inner content_placement=&#8221;bottom&#8221;][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<h4 style=\"text-align: left;\"><span style=\"color: #69abb4;\"><strong><span style=\"color: #aa689e;\">Pathophysiology of Alzheimer&#8217;s disease <\/span><\/strong><\/span><\/h4>\n<p>[\/vc_column_text][vc_column_text css=&#8221;&#8221;]Alzheimer&#8217;s disease is a progressive neurodegenerative disorder, with neuronal degeneration in the hippocampus gradually spreading to the whole brain.<\/p>\n<p>The pathophysiology of Alzheimer&#8217;s disease is based on a complex cascade of cellular and biochemical events. It is characterized by the extraneuronal accumulation of \u03b2-amyloid proteins in the form of plaques, and the intraneuronal accumulation of hyperphosphorylated tau proteins in the form of neurofibrillary degeneration. These plaques and neurofibrillary degenerations lead to progressive neuronal loss and synaptic degeneration.<\/p>\n<p>The very progressive development of these two specific lesions is associated with non-specific pathological mechanisms accelerating neuronal suffering and death: oxidative stress, neuroinflammation and mitochondrial damage.<\/p>\n<p>Mitochondria are intracellular organelles that provide the energy essential for neuron function. In addition, oxidative stress, when not sufficiently controlled by the immune system, becomes powerfully neurotoxic. In addition, a growing body of scientific work underlines the importance of neuroinflammation and the cells surrounding neurons &#8211; astrocytes and microglia &#8211; in the pathophysiological cascade of Alzheimer&#8217;s disease. Finally, changes in the composition of the intestinal microbiome may also play a role in Alzheimer&#8217;s disease.[\/vc_column_text][vc_single_image image=&#8221;5910&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221; css=&#8221;&#8221;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=&#8221;&#8221;]<\/p>\n<h4 style=\"text-align: left;\"><span style=\"color: #69abb4;\"><strong><span style=\"color: #aa689e;\">The role of the brain-gut-microbiota axis in Alzheimer&#8217;s disease <\/span><\/strong><\/span><\/h4>\n<p>[\/vc_column_text][vc_column_text css=&#8221;&#8221;]The immune system is responsible for bidirectional communication between the gut and the brain. Numerous studies have demonstrated the involvement of disruptions to the brain-microbiota-gut axis in the pathophysiology of neurological conditions such as Alzheimer&#8217;s disease (Doifode et al., 2021).[\/vc_column_text][vc_single_image image=&#8221;5909&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221; css=&#8221;&#8221;][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; css=&#8221;.vc_custom_1750772151539{padding-bottom: 50px !important;background-color: #FFFFFF !important;}&#8221;][vc_column][vc_column_text css=&#8221;&#8221;]<\/p>\n<h4 style=\"text-align: left;\"><span style=\"color: #69abb4;\"><strong><span style=\"color: #aa689e;\">Brain and photobiomodulation <\/span><\/strong><\/span><\/h4>\n<p>[\/vc_column_text][vc_column_text css=&#8221;&#8221;]Photobiomodulation therapy can benefit a wide range of brain disorders by targeting mitochondria, thereby reducing inflammation and apoptosis, and increasing cerebral blood flow and oxygenation. [\/vc_column_text][vc_single_image image=&#8221;5908&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221; css=&#8221;&#8221;][vc_column_text css=&#8221;&#8221;]<\/p>\n<p style=\"text-align: center;\">The therapeutic contribution of PBM could be significant for many neurological pathologies.<\/p>\n<p>[\/vc_column_text][vc_single_image image=&#8221;5911&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221; css=&#8221;&#8221;][vc_row_inner css=&#8221;.vc_custom_1751013826145{margin-right: 90px !important;margin-left: 90px !important;background-color: #D8BED3 !important;border-radius: 25px !important;}&#8221; mobile_margin_left=&#8221;10&#8243; mobile_margin_right=&#8221;10&#8243;][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<h4 style=\"text-align: center;\">Photobiomodulation is now emerging as a potential treatment for Alzheimer&#8217;s-type dementia.<\/h4>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; gap=&#8221;10&#8243; equal_height=&#8221;yes&#8221; css=&#8221;.vc_custom_1751623680897{margin-bottom: 0px !important;}&#8221;][vc_column width=&#8221;1\/3&#8243; css=&#8221;.vc_custom_1753876420294{border-top-width: 2px !important;border-right-width: 2px !important;border-bottom-width: 2px !important;border-left-width: 2px !important;padding-top: 35px !important;padding-right: 21px !important;padding-bottom: 50px !important;padding-left: 21px !important;border-left-style: solid !important;border-right-style: solid !important;border-top-style: solid !important;border-bottom-style: solid !important;border-radius: 30px !important;border-color: #DBE7E6 !important;}&#8221; mobile_padding_bottom=&#8221;20&#8243;][vc_single_image image=&#8221;5298&#8243; img_size=&#8221;150&#215;150&#8243; css=&#8221;.vc_custom_1752654287133{margin-bottom: 0px !important;margin-left: 0px !important;}&#8221;][vc_column_text css=&#8221;.vc_custom_1753089599267{margin-bottom: 20px !important;}&#8221;]<\/p>\n<h5><span style=\"color: #af6ba3;\">The<strong>\u0415ssai clinique pivot <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05926011\" target=\"_blank\" rel=\"noopener\">LIGHT4LIFE<\/a><\/strong><strong> (NCT05926011): underway to evaluate REGEnLIFE technology on<\/strong><strong>Alzheimer&#8217;s<\/strong><strong> patients<\/strong><\/span><\/h5>\n<p>[\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1753089632036{margin-right: 0px !important;margin-bottom: 0px !important;margin-left: 0px !important;border-left-width: 0px !important;padding-right: 0px !important;}&#8221;]RGn600, a new version of REGEnLIFE technology, is currently being evaluated in a multi-center, double-blind, randomized clinical trial in partnership with Toulouse University Hospital&#8217;s G\u00e9rontop\u00f4le and other investigating centers.[\/vc_column_text][vc_row_inner el_disable_desktop=&#8221;1&#8243; el_disable_tablet=&#8221;1&#8243; mobile_padding_top=&#8221;33&#8243; el_id=&#8221;MOVILES&#8221; css=&#8221;.vc_custom_1751391009028{padding-left: 12px !important;}&#8221;][vc_column_inner]<style type=\"text\/css\">.thegem-button-6a210883a178c5403 .gem-button {font-size: 22px;padding-left: 20px;padding-right: 12px;margin-top: 0px;}@media (max-width: 767px) {.thegem-button-6a210883a178c5403 .gem-button {padding-left: 25px;}}.thegem-button-6a210883a178c5403 .gem-button svg {fill: #000000;}.thegem-button-6a210883a178c5403 .gem-button:hover svg {fill: #FFFFFF;}<\/style><div class=\"gem-button-container gem-button-position-inline thegem-button-6a210883a178c5403 custom-button-seo-agency   \"  ><a class=\"gem-button gem-button-size-tiny gem-button-style-outline gem-button-text-weight-thin gem-button-border-2 gem-button-no-uppercase\" data-ll-effect=\"drop-right-without-wrap\" style=\"border-radius: 100px;border-color: #000000;color: #000000;\" onmouseleave=\"this.style.borderColor='#000000';this.style.backgroundColor='transparent';this.style.color='#000000';\" onmouseenter=\"this.style.backgroundColor='#000000';this.style.color='#FFFFFF';\" href=\"https:\/\/regen.mediartia.com\/alzheimer-physiopathologie\/#light4life\" target=\"_self\">Learn more<\/a><\/div> [\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column width=&#8221;1\/3&#8243; css=&#8221;.vc_custom_1753876492577{border-top-width: 2px !important;border-right-width: 2px !important;border-bottom-width: 2px !important;border-left-width: 2px !important;padding-top: 35px !important;padding-right: 21px !important;padding-bottom: 20px !important;padding-left: 21px !important;border-left-style: solid !important;border-right-style: solid !important;border-top-style: solid !important;border-bottom-style: solid !important;border-radius: 30px !important;border-color: #DBE7E6 !important;}&#8221; mobile_padding_bottom=&#8221;20&#8243;][vc_single_image image=&#8221;5359&#8243; img_size=&#8221;150&#215;150&#8243; css=&#8221;.vc_custom_1752654299039{margin-bottom: 0px !important;margin-left: 0px !important;}&#8221;][vc_column_text css=&#8221;.vc_custom_1753089678374{margin-bottom: 20px !important;}&#8221;]<\/p>\n<h5><span style=\"color: #af6ba3;\"><strong>Pilot clinical trial of<\/strong><strong>REGEnLIFE&#8217;s<\/strong><strong>photomedical technology<\/strong><strong>for the treatment of<\/strong><strong>Alzheimer&#8217;s disease<\/strong><\/span><\/h5>\n<p>[\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1750771049887{margin-right: 0px !important;margin-bottom: 0px !important;margin-left: 0px !important;border-left-width: 0px !important;padding-right: 0px !important;}&#8221;]RGn was shown to be safe and well tolerated in a pilot clinical study of Alzheimer&#8217;s disease.[\/vc_column_text][vc_row_inner el_disable_desktop=&#8221;1&#8243; el_disable_tablet=&#8221;1&#8243; mobile_padding_top=&#8221;33&#8243; el_id=&#8221;MOVILES&#8221; css=&#8221;.vc_custom_1751391009028{padding-left: 12px !important;}&#8221;][vc_column_inner]<style type=\"text\/css\">.thegem-button-6a210883a181d688 .gem-button {font-size: 22px;padding-left: 20px;padding-right: 12px;margin-top: 0px;}@media (max-width: 767px) {.thegem-button-6a210883a181d688 .gem-button {padding-left: 25px;}}.thegem-button-6a210883a181d688 .gem-button svg {fill: #000000;}.thegem-button-6a210883a181d688 .gem-button:hover svg {fill: #FFFFFF;}<\/style><div class=\"gem-button-container gem-button-position-inline thegem-button-6a210883a181d688 custom-button-seo-agency   \"  ><a class=\"gem-button gem-button-size-tiny gem-button-style-outline gem-button-text-weight-thin gem-button-border-2 gem-button-no-uppercase\" data-ll-effect=\"drop-right-without-wrap\" style=\"border-radius: 100px;border-color: #000000;color: #000000;\" onmouseleave=\"this.style.borderColor='#000000';this.style.backgroundColor='transparent';this.style.color='#000000';\" onmouseenter=\"this.style.backgroundColor='#000000';this.style.color='#FFFFFF';\" href=\"https:\/\/regen.mediartia.com\/alzheimer-physiopathologie\/#pilote\" target=\"_self\">Learn more<\/a><\/div> [\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column width=&#8221;1\/3&#8243; css=&#8221;.vc_custom_1753876512392{border-top-width: 2px !important;border-right-width: 2px !important;border-bottom-width: 2px !important;border-left-width: 2px !important;padding-top: 35px !important;padding-right: 21px !important;padding-bottom: 20px !important;padding-left: 21px !important;border-left-style: solid !important;border-right-style: solid !important;border-top-style: solid !important;border-bottom-style: solid !important;border-radius: 30px !important;border-color: #DBE7E6 !important;}&#8221;][vc_single_image image=&#8221;5360&#8243; img_size=&#8221;150&#215;150&#8243; css=&#8221;.vc_custom_1752654311764{margin-bottom: 0px !important;margin-left: 0px !important;}&#8221;][vc_column_text css=&#8221;.vc_custom_1753089851965{margin-bottom: 20px !important;}&#8221;]<\/p>\n<h5><span style=\"color: #af6ba3;\"><strong>Preclinical studies<\/strong><strong>by REGEnLIFE<\/strong><\/span><\/h5>\n<p>[\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1753089888417{margin-right: 0px !important;margin-bottom: 0px !important;margin-left: 0px !important;border-left-width: 0px !important;padding-right: 0px !important;}&#8221;]In preclinical studies, the RGn500 prototype has been shown to normalize memory deficits and biochemical changes in the A\u03b225-35 mouse model, mimicking the pathological features of Alzheimer&#8217;s disease.[\/vc_column_text][vc_row_inner el_disable_desktop=&#8221;1&#8243; el_disable_tablet=&#8221;1&#8243; mobile_padding_top=&#8221;33&#8243; el_id=&#8221;MOVILES&#8221; css=&#8221;.vc_custom_1751391009028{padding-left: 12px !important;}&#8221;][vc_column_inner]<style type=\"text\/css\">.thegem-button-6a210883a18a63593 .gem-button {font-size: 22px;padding-left: 20px;padding-right: 12px;margin-top: 0px;}@media (max-width: 767px) {.thegem-button-6a210883a18a63593 .gem-button {padding-left: 25px;}}.thegem-button-6a210883a18a63593 .gem-button svg {fill: #000000;}.thegem-button-6a210883a18a63593 .gem-button:hover svg {fill: #FFFFFF;}<\/style><div class=\"gem-button-container gem-button-position-inline thegem-button-6a210883a18a63593 custom-button-seo-agency   \"  ><a class=\"gem-button gem-button-size-tiny gem-button-style-outline gem-button-text-weight-thin gem-button-border-2 gem-button-no-uppercase\" data-ll-effect=\"drop-right-without-wrap\" style=\"border-radius: 100px;border-color: #000000;color: #000000;\" onmouseleave=\"this.style.borderColor='#000000';this.style.backgroundColor='transparent';this.style.color='#000000';\" onmouseenter=\"this.style.backgroundColor='#000000';this.style.color='#FFFFFF';\" href=\"https:\/\/regen.mediartia.com\/alzheimer-physiopathologie\/#precliniques\" target=\"_self\">Learn more<\/a><\/div> [\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; gap=&#8221;10&#8243; content_placement=&#8221;top&#8221; el_disable_mobile=&#8221;1&#8243; css=&#8221;.vc_custom_1751623655023{margin-bottom: 0px !important;}&#8221; el_id=&#8221;DESKTOP&#8221;][vc_column width=&#8221;1\/3&#8243; css=&#8221;.vc_custom_1751363825223{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 21px !important;padding-right: 21px !important;padding-left: 21px !important;border-radius: 30px !important;border-color: #DBE7E6 !important;}&#8221; mobile_padding_bottom=&#8221;20&#8243;]<style type=\"text\/css\">.thegem-button-6a210883a192d4562 .gem-button {font-size: 22px;padding-left: 20px;padding-right: 12px;margin-top: 0px;}@media (max-width: 767px) {.thegem-button-6a210883a192d4562 .gem-button {padding-left: 25px;}}.thegem-button-6a210883a192d4562 .gem-button svg {fill: #000000;}.thegem-button-6a210883a192d4562 .gem-button:hover svg {fill: #FFFFFF;}<\/style><div class=\"gem-button-container gem-button-position-inline thegem-button-6a210883a192d4562 custom-button-seo-agency   \"  ><a class=\"gem-button gem-button-size-tiny gem-button-style-outline gem-button-text-weight-thin gem-button-border-2 gem-button-no-uppercase\" data-ll-effect=\"drop-right-without-wrap\" style=\"border-radius: 100px;border-color: #000000;color: #000000;\" onmouseleave=\"this.style.borderColor='#000000';this.style.backgroundColor='transparent';this.style.color='#000000';\" onmouseenter=\"this.style.backgroundColor='#000000';this.style.color='#FFFFFF';\" href=\"https:\/\/regen.mediartia.com\/alzheimer-physiopathologie\/#light4life\" target=\"_self\">Learn more<\/a><\/div> [\/vc_column][vc_column width=&#8221;1\/3&#8243; css=&#8221;.vc_custom_1751363998950{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 21px !important;padding-right: 21px !important;padding-left: 21px !important;border-radius: 30px !important;border-color: #DBE7E6 !important;}&#8221; mobile_padding_bottom=&#8221;20&#8243;]<style type=\"text\/css\">.thegem-button-6a210883a19b32759 .gem-button {font-size: 22px;padding-left: 20px;padding-right: 12px;margin-top: 0px;}@media (max-width: 767px) {.thegem-button-6a210883a19b32759 .gem-button {padding-left: 25px;}}.thegem-button-6a210883a19b32759 .gem-button svg {fill: #000000;}.thegem-button-6a210883a19b32759 .gem-button:hover svg {fill: #FFFFFF;}<\/style><div class=\"gem-button-container gem-button-position-inline thegem-button-6a210883a19b32759 custom-button-seo-agency   \"  ><a class=\"gem-button gem-button-size-tiny gem-button-style-outline gem-button-text-weight-thin gem-button-border-2 gem-button-no-uppercase\" data-ll-effect=\"drop-right-without-wrap\" style=\"border-radius: 100px;border-color: #000000;color: #000000;\" onmouseleave=\"this.style.borderColor='#000000';this.style.backgroundColor='transparent';this.style.color='#000000';\" onmouseenter=\"this.style.backgroundColor='#000000';this.style.color='#FFFFFF';\" href=\"https:\/\/regen.mediartia.com\/alzheimer-physiopathologie\/#pilote\" target=\"_self\">Learn more<\/a><\/div> [\/vc_column][vc_column width=&#8221;1\/3&#8243; css=&#8221;.vc_custom_1751364008635{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 21px !important;padding-right: 21px !important;padding-left: 21px !important;border-radius: 30px !important;border-color: #DBE7E6 !important;}&#8221;]<style type=\"text\/css\">.thegem-button-6a210883a1a384900 .gem-button {font-size: 22px;padding-left: 20px;padding-right: 12px;margin-top: 0px;}@media (max-width: 767px) {.thegem-button-6a210883a1a384900 .gem-button {padding-left: 25px;}}.thegem-button-6a210883a1a384900 .gem-button svg {fill: #000000;}.thegem-button-6a210883a1a384900 .gem-button:hover svg {fill: #FFFFFF;}<\/style><div class=\"gem-button-container gem-button-position-inline thegem-button-6a210883a1a384900 custom-button-seo-agency   \"  ><a class=\"gem-button gem-button-size-tiny gem-button-style-outline gem-button-text-weight-thin gem-button-border-2 gem-button-no-uppercase\" data-ll-effect=\"drop-right-without-wrap\" style=\"border-radius: 100px;border-color: #000000;color: #000000;\" onmouseleave=\"this.style.borderColor='#000000';this.style.backgroundColor='transparent';this.style.color='#000000';\" onmouseenter=\"this.style.backgroundColor='#000000';this.style.color='#FFFFFF';\" href=\"https:\/\/regen.mediartia.com\/alzheimer-physiopathologie\/#precliniques\" target=\"_self\">Learn more<\/a><\/div> [\/vc_column][\/vc_row][vc_row][vc_column]<div class=\"clearboth\"><\/div><style>#thegem-divider-6a210883a1a80 {margin-top: 50px !important;}<\/style><div id=\"thegem-divider-6a210883a1a80\" class=\"gem-divider  \" style=\"\" ><\/div>[\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; custom_css_code=&#8221;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&#8221; css=&#8221;.vc_custom_1753876454681{margin-bottom: 0px !important;padding-top: 85px !important;padding-bottom: 85px !important;background-color: #FFFFFF !important;}&#8221; el_id=&#8221;light4life&#8221;][vc_column css=&#8221;.vc_custom_1726578677849{padding-top: 0px !important;}&#8221;][vc_row_inner content_placement=&#8221;bottom&#8221;][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<h4 style=\"text-align: left;\"><span style=\"color: #69abb4;\"><strong><span style=\"color: #aa689e;\">The \u0415ssai clinique pivot Light4Life: underway to evaluate REGEnLIFE technology on Alzheimer&#8217;s patients<\/span><\/strong><\/span><\/h4>\n<p>[\/vc_column_text][vc_column_text css=&#8221;&#8221;]<strong>RGn600, a new version of REGEnLIFE technology, is currently being evaluated in a multi-center, double-blind, randomized clinical trial in partnership with Toulouse University Hospital&#8217;s G\u00e9rontop\u00f4le and other investigating centers.<\/strong><\/p>\n<p><strong>Context<\/strong><\/p>\n<p>Alzheimer&#8217;s disease (AD) represents a serious public health problem, for which no clearly effective treatment is currently available.<\/p>\n<p>The &#8220;REGEnLIFE RGn600&#8221; is a photobiomodulation (PBM) medical device targeting the brain and gut. Results from an initial pilot clinical trial demonstrated safety and patient compliance, and revealed efficacy trends in 53 patients with mild-to-moderate Alzheimer&#8217;s disease treated with PBM therapy (Blivet et al., A randomized, double-blind, and sham-controlled trial of an innovative brain-gut photobiomodulation therapy: safety and patient compliance. J Alzheimer&#8217;s Dis. 2022, 90: 2). This study provided valuable information for the design of our pivotal therapeutic trial, which is currently evaluating the cognitive benefits of photobiomodulation therapy in a larger sample of Alzheimer&#8217;s disease patients.<\/p>\n<p><strong>Objectives<\/strong><\/p>\n<p>The primary endpoint of this pivotal clinical trial is the evolution of patients&#8217; cognition after 26 weeks of PBM therapy, measured by the ADAS-cog score. Neuropsychological function, autonomy, overall clinical response, quality of life, blood and fecal markers and medico-economic value are studied as secondary endpoints. The safety of RGn600 treatment was also evaluated.<\/p>\n<p><strong>Methods<\/strong><\/p>\n<p>The RGn600 is a non-invasive medical device, manufactured by REGEnLIFE, which comes in the form of a helmet and abdominal belt combining PBM technology from red to near-infrared wavelengths and static magnetic stimulation.<\/p>\n<p>A pivotal multicenter, double-blind, randomized, controlled clinical trial has been initiated in July 2023 at the Toulouse University Hospital G\u00e9rontopole. A total of 108 patients with NIA-AA diagnostic criteria for AD will be included and randomized into a treatment group (n=54) and a sham group (n=54). They will receive 84 sessions of 20 min PBM therapy over 26 weeks.<\/p>\n<p><strong>Results<\/strong><\/p>\n<p>The first patient visit took place in July 2023. Statistical analysis will be performed in the full analysis set, the per-protocol populations and the treated set.<\/p>\n<p><strong>Conclusion<\/strong><\/p>\n<p>REGEnLIFE RGn600 brain-gut PBM therapy, as a treatment, could potentially offer a safe, well-tolerated method, with medical and economic benefits, to treat patients with mild to moderate AD. The design of this study, named LIGHT4LIFE, evaluating such an innovative medical device for the treatment of AD is detailed <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05926011\" target=\"_blank\" rel=\"noopener\">(NCT05926011<\/a>). The advantages and limitations of this clinical trial will be discussed.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css=&#8221;.vc_custom_1753876695110{padding-top: 85px !important;padding-bottom: 85px !important;}&#8221; el_id=&#8221;pilot&#8221;][vc_column][vc_row_inner content_placement=&#8221;bottom&#8221;][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<h4 style=\"text-align: left;\"><span style=\"color: #69abb4;\"><strong><span style=\"color: #aa689e;\">Pilot clinical trial of REGEnLIFE&#8217;s photomedical technology for the treatment of Alzheimer&#8217;s disease<\/span><\/strong><\/span><\/h4>\n<p>[\/vc_column_text][vc_column_text css=&#8221;&#8221;]<strong>RGn was shown to be safe and well tolerated in a pilot clinical study of Alzheimer&#8217;s disease.<\/strong><\/p>\n<p>In March 2021, REGEnLIFE announced encouraging initial results from its first pilot clinical study evaluating its medical device on Alzheimer&#8217;s disease. They were presented at the 15th International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases (AD\/PD 2021) from March 9 to 14, by Professor Jacques Touchon, scientific advisor on the clinical trial.<\/p>\n<p>REGEnLIFE&#8217;s innovative, non-invasive technology, which is the subject of this therapeutic trial, is based on a photobiomodulation technique designed to target the brain and gut, using a helmet and abdominal breastplate. This novel medical device in photo-medicine, called RGn, aims to stimulate cells in the brain and intestine and regulate inflammation, so as to improve cognitive functioning and behavior. It targets inflammation on the brain-gut axis, which is thought to be involved in the development of Alzheimer&#8217;s disease and other neurological disorders.<\/p>\n<p><span style=\"color: #69abb4;\"><strong>Design of REGEnLIFE&#8217;s pilot clinical study in Alzheimer&#8217;s disease:<\/strong><\/span><\/p>\n<p>Pilot study evaluating the safety and efficacy of a photobiomodulation prototype, RGn, developed by REGEnLIFE, on cognitive performance in patients with mild to moderate Alzheimer&#8217;s disease. <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03672474\" target=\"_blank\" rel=\"noopener\">(NCT03672474)<\/a>[\/vc_column_text][vc_single_image image=&#8221;5361&#8243; img_size=&#8221;large&#8221; alignment=&#8221;center&#8221; css=&#8221;&#8221;][vc_column_text css=&#8221;&#8221;]The trial involved adult volunteers aged 55 to 85 with mild to moderate Alzheimer&#8217;s disease. Equipped with a helmet and a photobiomodulation abdominal belt, these patients benefited from 40 25-minute sessions spread over two months, and were evaluated by a series of tests throughout the study and up to one month after stopping treatment. This double-blind, randomized, single-center, placebo-controlled clinical trial began in 2018 and ended prematurely in 2020 due to the COVID-19 pandemic. Of the 64 planned, 53 patients were randomized into two groups (treated and placebo) and 43 patients were able to benefit from treatment for the planned duration.<\/p>\n<ul>\n<li>Treatment group shows trends towards cognitive improvement, executive function, language comprehension and verbal memory compared to placebo group<\/li>\n<li>REGEnLIFE&#8217;s technology has been shown to be safe and well tolerated by treated patients<\/li>\n<li>These results open up new prospects for the development of this novel device for the prevention and treatment of neurological disorders using both cerebral and intestinal stimulation.<\/li>\n<\/ul>\n<p>The primary efficacy endpoint was measured by the change in ADAS-Cog (Alzheimer&#8217;s Disease Assessment Scale) total score between inclusion and two months of treatment. In terms of safety, the REGEnLIFE RGn device was found to be safe, with no serious adverse events reported. Compliance with treatment sessions was very good for the vast majority of patients (92%), confirming the device&#8217;s good tolerance. Although the primary efficacy criterion was not met in statistical terms, there was a clear trend towards improvement in a range of cognitive functions. The results of this pilot study showed that REGEnLIFE technology is safe and well tolerated by patients. These very encouraging safety and efficacy results need to be confirmed in a pivotal or phase III clinical trial.<\/p>\n<p>&#8220;To be effective, the therapeutic strategy for Alzheimer&#8217;s disease needs to address several targets. Drug treatments targeting the two proteins characteristic of the Alzheimer process (beta-amyloid and tau proteins) need to be complemented by other therapies targeting less specific but very important mechanisms in the physiopathological cascade, such as inflammation and oxidative stress. The photobiomodulation technology developed by REGEnLIFE acts far upstream on this cascade (mitochondria, inflammation, oxidative stress). It could be the non-medicinal complement to the therapeutic strategy of the future. What&#8217;s more, REGEnLIFE&#8217;s technology enables us to act on both the brain and the intestine, a considerable advantage given the importance of the brain-intestine axis and the microbiota in neurological disorders&#8221;, adds Professor Jacques Touchon, neurologist and psychiatrist, scientific advisor on this clinical trial.<\/p>\n<p><span style=\"color: #69abb4;\"><strong>In a nutshell:<\/strong><\/span><\/p>\n<ul>\n<li><strong>This pilot study proved the feasibility and tolerability of REGEnLIFE&#8217;s RGn device.<\/strong><\/li>\n<li><strong>The RGn device is also safe and enables non-invasive treatment.<\/strong><\/li>\n<li><strong>Patients were highly compliant with RGn treatment.<\/strong><\/li>\n<li><strong>This study showed trends in cognitive efficacy despite the reduced number of patients due to the premature termination of the study because of COVID-19.<\/strong><\/li>\n<li><strong>This study also provides valuable insights for the design of the next phase of clinical trials aimed at demonstrating, on a larger scale, the cognitive benefit of RGn treatment.<\/strong><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>References :<\/strong><\/p>\n<p>Blivet et al, Safety and feasibility of the RGn, an innovative brain-gut photobiomodulation device, in mild-to-moderate Alzheimer&#8217;s Disease patients: a randomized, double-blind and sham-controlled trial, Oral communication AD\/PD 2021.<\/p>\n<p><a href=\"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full\/10.1016\/j.trci.2017.12.003\" target=\"_blank\" rel=\"noopener\">Guillaume Blivet, Johann Meunier, Francois J. Roman, Jacques Touchon &#8211; Neuroprotective effect of a new photobiomodulation technique against A\u03b225-35 peptide-induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer&#8217;s disease suggested, February 2018<\/a><\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32617993\/\" target=\"_blank\" rel=\"noopener\">Yayi Sun et al. &#8211; Intra-gastrointestinal amyloid-\u03b21-42 oligomers perturb enteric function and induce Alzheimer&#8217;s disease pathology, July 2020 <\/a><\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6326209\/\" target=\"_blank\" rel=\"noopener\">Karol Kowalski and Agata Mulak &#8211; Brain-Gut-Microbiota Axis in Alzheimer&#8217;s Disease, January 2019<\/a><\/p>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; custom_css_code=&#8221;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&#8221; css=&#8221;.vc_custom_1753876521045{margin-bottom: 0px !important;padding-top: 85px !important;padding-bottom: 85px !important;background-color: #FFFFFF !important;}&#8221; el_id=&#8221;preclinical&#8221;][vc_column css=&#8221;.vc_custom_1726578677849{padding-top: 0px !important;}&#8221;][vc_row_inner content_placement=&#8221;bottom&#8221;][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<h4 style=\"text-align: left;\"><span style=\"color: #69abb4;\"><strong><span style=\"color: #aa689e;\">Preclinical studies conducted by REGEnLIFE<\/span><\/strong><\/span><\/h4>\n<p>[\/vc_column_text][vc_column_text css=&#8221;&#8221;]<strong>In preclinical studies, the RGn500 prototype has been shown to normalize memory deficits and biochemical changes in the A\u03b225-35 mouse model, mimicking the pathological features of AD.<\/strong>[\/vc_column_text][vc_single_image image=&#8221;5362&#8243; img_size=&#8221;large&#8221; alignment=&#8221;center&#8221; css=&#8221;&#8221;][vc_column_text css=&#8221;&#8221;]In preclinical studies, the RGn500 prototype has been shown to normalize memory deficits and biochemical changes in the A\u03b225-35 mouse model, mimicking the pathological features of AD.<\/p>\n<p>Interestingly, this neuroprotective effect, in the configurations studied, was only observed when both the head and abdomen were exposed (but not the head only or the abdomen only), suggesting that several mechanisms are involved, including direct activation of cellular chromophores at the neuronal level and indirect effects resulting from abdominal exposure. It also suggests that double PBM exposure, on the head and abdomen, would increase therapeutic efficacy.<\/p>\n<p>[\/vc_column_text][vc_single_image image=&#8221;5363&#8243; img_size=&#8221;large&#8221; alignment=&#8221;center&#8221; css=&#8221;&#8221;][vc_single_image image=&#8221;5364&#8243; img_size=&#8221;large&#8221; alignment=&#8221;center&#8221; css=&#8221;&#8221;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row equal_height=&#8221;yes&#8221; content_placement=&#8221;top&#8221; custom_css_code=&#8221;LmdlbS1pbWFnZS1jZW50ZXJlZC1ib3glMjAlN0IlMEElMjAlMjAlMjAlMjBtYXJnaW4tYm90dG9tJTNBJTIwMCUzQiUwQSU3RCUwQS5pbWctYm9yZGVyLXJhZGl1cyUyMGltZyU3QiUwQSUyMCUyMCUyMCUyMGJvcmRlci1yYWRpdXMlM0ElMjAzM3B4JTNCJTBBJTdEJTBBLmN1c3RvbS1pbmZvdGV4dCUyMCU3QiUwQSUyMCUyMCUyMCUyMHdpZHRoJTNBJTIwMjIwcHglM0IlMEElN0QlMEElNDBtZWRpYSUyOG1heC13aWR0aCUzQSUyMDk5MXB4JTI5JTdCJTBBJTIwJTIwJTIwJTIwLmN1c3RvbS1pbmZvdGV4dCUyMCU3QiUwQSUyMCUyMCUyMCUyMCUyMCUyMCUyMCUyMHdpZHRoJTNBJTIwMjAwcHglM0IlMEElMjAlMjAlMjAlMjAlN0QlMEElN0Q=&#8221; thegem_revesrse_columns_mobile=&#8221;true&#8221; css=&#8221;.vc_custom_1751013794817{margin-bottom: 0px !important;padding-top: 85px !important;padding-bottom: 85px !important;}&#8221; tablet_padding_top=&#8221;160&#8243; el_class=&#8221;CONTENEDORPIRATA&#8221; mobile_padding_top=&#8221;45&#8243;][vc_column width=&#8221;1\/2&#8243; css=&#8221;.vc_custom_1750698481768{padding-top: 0px !important;padding-right: 75px&#8230;<\/p>\n","protected":false},"author":1,"featured_media":5173,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-5372","page","type-page","status-publish","has-post-thumbnail"],"acf":[],"_links":{"self":[{"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/pages\/5372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/comments?post=5372"}],"version-history":[{"count":7,"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/pages\/5372\/revisions"}],"predecessor-version":[{"id":6083,"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/pages\/5372\/revisions\/6083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/media\/5173"}],"wp:attachment":[{"href":"https:\/\/regen.mediartia.com\/en\/wp-json\/wp\/v2\/media?parent=5372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}